restriction inhibitor Search Results


anti shp1 ptpn6  (Boster Bio)
94
Boster Bio anti shp1 ptpn6
Anti Shp1 Ptpn6, supplied by Boster Bio, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti shp1 ptpn6/product/Boster Bio
Average 94 stars, based on 1 article reviews
anti shp1 ptpn6 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
typeone restriction inhibitor  (Lucigen Corp)
90
Lucigen Corp typeone restriction inhibitor
Typeone Restriction Inhibitor, supplied by Lucigen Corp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/typeone restriction inhibitor/product/Lucigen Corp
Average 90 stars, based on 1 article reviews
typeone restriction inhibitor - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
restriction inhibitor  (Epicentre Biotechnologies)
90
Epicentre Biotechnologies restriction inhibitor
Restriction Inhibitor, supplied by Epicentre Biotechnologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/restriction inhibitor/product/Epicentre Biotechnologies
Average 90 stars, based on 1 article reviews
restriction inhibitor - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
gcpii inhibitors  (Johns Hopkins HealthCare)
90
Johns Hopkins HealthCare gcpii inhibitors
Gcpii Inhibitors, supplied by Johns Hopkins HealthCare, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gcpii inhibitors/product/Johns Hopkins HealthCare
Average 90 stars, based on 1 article reviews
gcpii inhibitors - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
restriction enzymes and protease inhibitors  (Boehringer Mannheim)
90
Boehringer Mannheim restriction enzymes and protease inhibitors
Restriction Enzymes And Protease Inhibitors, supplied by Boehringer Mannheim, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/restriction enzymes and protease inhibitors/product/Boehringer Mannheim
Average 90 stars, based on 1 article reviews
restriction enzymes and protease inhibitors - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
gut-restricted rock inhibitors  (Redx Pharma)
90
Redx Pharma gut-restricted rock inhibitors
New potential therapeutic targets for IBD with differentiated MoAs. The diversity of IBD pathological mechanisms represents an opportunity for novel treatment approaches. Examples of therapeutic candidates in preclinical development include LBPs, which restore eubiosis by decolonizing pathobionts and repopulating commensal microbiota. Supplementation of RvE1 and inhibition of PAI-1 induce enterocyte proliferation and mucosal healing. An inhibitor of MLCK prevents its trafficking to TJs, avoiding barrier junction damage. A neutralizing MAb against IgA-coated bacteria-derived toxins can also prevent barrier <t>damage.</t> <t>Inhibitors</t> of SPNS2 abrogate leukocyte trafficking to sites of inflammation. BRD4 and Fbxo3 antagonists inhibit proinflammatory mediators, and an inhibitor of GCPII may abrogate local neuroinflammatory signals. Opportunities for treatment of fibrotic complications include neutralizing anti-TL1A monoclonal antibodies and inhibitors of <t>ROCK.</t> Programmable biopolymers are in development to enable tissue reconstruction and healing of the fistula tract. Abbreviations: BRD4, bromodomain-containing protein 4; GCPII, glutamate carboxypeptidase II; IBD, inflammatory bowel diseases; IgA, immunoglobin A; LBP, live biotherapeutic product; MAb, monoclonal antibody; MLCK, myosin light chain kinase; MoA, mechanism of action; PAI-1, plasminogen activator inhibitor–1; ROCK, rho-associated coiled-coil-containing protein kinase; RvE1, resolvin E1; TJ, tight junction.
Gut Restricted Rock Inhibitors, supplied by Redx Pharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gut-restricted rock inhibitors/product/Redx Pharma
Average 90 stars, based on 1 article reviews
gut-restricted rock inhibitors - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
ocr type 1 restriction inhibitor  (Epicentre Biotechnologies)
90
Epicentre Biotechnologies ocr type 1 restriction inhibitor
New potential therapeutic targets for IBD with differentiated MoAs. The diversity of IBD pathological mechanisms represents an opportunity for novel treatment approaches. Examples of therapeutic candidates in preclinical development include LBPs, which restore eubiosis by decolonizing pathobionts and repopulating commensal microbiota. Supplementation of RvE1 and inhibition of PAI-1 induce enterocyte proliferation and mucosal healing. An inhibitor of MLCK prevents its trafficking to TJs, avoiding barrier junction damage. A neutralizing MAb against IgA-coated bacteria-derived toxins can also prevent barrier <t>damage.</t> <t>Inhibitors</t> of SPNS2 abrogate leukocyte trafficking to sites of inflammation. BRD4 and Fbxo3 antagonists inhibit proinflammatory mediators, and an inhibitor of GCPII may abrogate local neuroinflammatory signals. Opportunities for treatment of fibrotic complications include neutralizing anti-TL1A monoclonal antibodies and inhibitors of <t>ROCK.</t> Programmable biopolymers are in development to enable tissue reconstruction and healing of the fistula tract. Abbreviations: BRD4, bromodomain-containing protein 4; GCPII, glutamate carboxypeptidase II; IBD, inflammatory bowel diseases; IgA, immunoglobin A; LBP, live biotherapeutic product; MAb, monoclonal antibody; MLCK, myosin light chain kinase; MoA, mechanism of action; PAI-1, plasminogen activator inhibitor–1; ROCK, rho-associated coiled-coil-containing protein kinase; RvE1, resolvin E1; TJ, tight junction.
Ocr Type 1 Restriction Inhibitor, supplied by Epicentre Biotechnologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ocr type 1 restriction inhibitor/product/Epicentre Biotechnologies
Average 90 stars, based on 1 article reviews
ocr type 1 restriction inhibitor - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
typeone restriction inhibitor  (Biosearch Technologies Inc)
90
Biosearch Technologies Inc typeone restriction inhibitor
New potential therapeutic targets for IBD with differentiated MoAs. The diversity of IBD pathological mechanisms represents an opportunity for novel treatment approaches. Examples of therapeutic candidates in preclinical development include LBPs, which restore eubiosis by decolonizing pathobionts and repopulating commensal microbiota. Supplementation of RvE1 and inhibition of PAI-1 induce enterocyte proliferation and mucosal healing. An inhibitor of MLCK prevents its trafficking to TJs, avoiding barrier junction damage. A neutralizing MAb against IgA-coated bacteria-derived toxins can also prevent barrier <t>damage.</t> <t>Inhibitors</t> of SPNS2 abrogate leukocyte trafficking to sites of inflammation. BRD4 and Fbxo3 antagonists inhibit proinflammatory mediators, and an inhibitor of GCPII may abrogate local neuroinflammatory signals. Opportunities for treatment of fibrotic complications include neutralizing anti-TL1A monoclonal antibodies and inhibitors of <t>ROCK.</t> Programmable biopolymers are in development to enable tissue reconstruction and healing of the fistula tract. Abbreviations: BRD4, bromodomain-containing protein 4; GCPII, glutamate carboxypeptidase II; IBD, inflammatory bowel diseases; IgA, immunoglobin A; LBP, live biotherapeutic product; MAb, monoclonal antibody; MLCK, myosin light chain kinase; MoA, mechanism of action; PAI-1, plasminogen activator inhibitor–1; ROCK, rho-associated coiled-coil-containing protein kinase; RvE1, resolvin E1; TJ, tight junction.
Typeone Restriction Inhibitor, supplied by Biosearch Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/typeone restriction inhibitor/product/Biosearch Technologies Inc
Average 90 stars, based on 1 article reviews
typeone restriction inhibitor - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
restriction inhibitors ma180e  (Lucigen Corp)
90
Lucigen Corp restriction inhibitors ma180e
New potential therapeutic targets for IBD with differentiated MoAs. The diversity of IBD pathological mechanisms represents an opportunity for novel treatment approaches. Examples of therapeutic candidates in preclinical development include LBPs, which restore eubiosis by decolonizing pathobionts and repopulating commensal microbiota. Supplementation of RvE1 and inhibition of PAI-1 induce enterocyte proliferation and mucosal healing. An inhibitor of MLCK prevents its trafficking to TJs, avoiding barrier junction damage. A neutralizing MAb against IgA-coated bacteria-derived toxins can also prevent barrier <t>damage.</t> <t>Inhibitors</t> of SPNS2 abrogate leukocyte trafficking to sites of inflammation. BRD4 and Fbxo3 antagonists inhibit proinflammatory mediators, and an inhibitor of GCPII may abrogate local neuroinflammatory signals. Opportunities for treatment of fibrotic complications include neutralizing anti-TL1A monoclonal antibodies and inhibitors of <t>ROCK.</t> Programmable biopolymers are in development to enable tissue reconstruction and healing of the fistula tract. Abbreviations: BRD4, bromodomain-containing protein 4; GCPII, glutamate carboxypeptidase II; IBD, inflammatory bowel diseases; IgA, immunoglobin A; LBP, live biotherapeutic product; MAb, monoclonal antibody; MLCK, myosin light chain kinase; MoA, mechanism of action; PAI-1, plasminogen activator inhibitor–1; ROCK, rho-associated coiled-coil-containing protein kinase; RvE1, resolvin E1; TJ, tight junction.
Restriction Inhibitors Ma180e, supplied by Lucigen Corp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/restriction inhibitors ma180e/product/Lucigen Corp
Average 90 stars, based on 1 article reviews
restriction inhibitors ma180e - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
tionally restricted inhibitors  (Conforma Therapeutics Corporation)
90
Conforma Therapeutics Corporation tionally restricted inhibitors
New potential therapeutic targets for IBD with differentiated MoAs. The diversity of IBD pathological mechanisms represents an opportunity for novel treatment approaches. Examples of therapeutic candidates in preclinical development include LBPs, which restore eubiosis by decolonizing pathobionts and repopulating commensal microbiota. Supplementation of RvE1 and inhibition of PAI-1 induce enterocyte proliferation and mucosal healing. An inhibitor of MLCK prevents its trafficking to TJs, avoiding barrier junction damage. A neutralizing MAb against IgA-coated bacteria-derived toxins can also prevent barrier <t>damage.</t> <t>Inhibitors</t> of SPNS2 abrogate leukocyte trafficking to sites of inflammation. BRD4 and Fbxo3 antagonists inhibit proinflammatory mediators, and an inhibitor of GCPII may abrogate local neuroinflammatory signals. Opportunities for treatment of fibrotic complications include neutralizing anti-TL1A monoclonal antibodies and inhibitors of <t>ROCK.</t> Programmable biopolymers are in development to enable tissue reconstruction and healing of the fistula tract. Abbreviations: BRD4, bromodomain-containing protein 4; GCPII, glutamate carboxypeptidase II; IBD, inflammatory bowel diseases; IgA, immunoglobin A; LBP, live biotherapeutic product; MAb, monoclonal antibody; MLCK, myosin light chain kinase; MoA, mechanism of action; PAI-1, plasminogen activator inhibitor–1; ROCK, rho-associated coiled-coil-containing protein kinase; RvE1, resolvin E1; TJ, tight junction.
Tionally Restricted Inhibitors, supplied by Conforma Therapeutics Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tionally restricted inhibitors/product/Conforma Therapeutics Corporation
Average 90 stars, based on 1 article reviews
tionally restricted inhibitors - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
conformationally restricted sulfonamide 48  (Merck & Co)
90
Merck & Co conformationally restricted sulfonamide 48
New potential therapeutic targets for IBD with differentiated MoAs. The diversity of IBD pathological mechanisms represents an opportunity for novel treatment approaches. Examples of therapeutic candidates in preclinical development include LBPs, which restore eubiosis by decolonizing pathobionts and repopulating commensal microbiota. Supplementation of RvE1 and inhibition of PAI-1 induce enterocyte proliferation and mucosal healing. An inhibitor of MLCK prevents its trafficking to TJs, avoiding barrier junction damage. A neutralizing MAb against IgA-coated bacteria-derived toxins can also prevent barrier <t>damage.</t> <t>Inhibitors</t> of SPNS2 abrogate leukocyte trafficking to sites of inflammation. BRD4 and Fbxo3 antagonists inhibit proinflammatory mediators, and an inhibitor of GCPII may abrogate local neuroinflammatory signals. Opportunities for treatment of fibrotic complications include neutralizing anti-TL1A monoclonal antibodies and inhibitors of <t>ROCK.</t> Programmable biopolymers are in development to enable tissue reconstruction and healing of the fistula tract. Abbreviations: BRD4, bromodomain-containing protein 4; GCPII, glutamate carboxypeptidase II; IBD, inflammatory bowel diseases; IgA, immunoglobin A; LBP, live biotherapeutic product; MAb, monoclonal antibody; MLCK, myosin light chain kinase; MoA, mechanism of action; PAI-1, plasminogen activator inhibitor–1; ROCK, rho-associated coiled-coil-containing protein kinase; RvE1, resolvin E1; TJ, tight junction.
Conformationally Restricted Sulfonamide 48, supplied by Merck & Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/conformationally restricted sulfonamide 48/product/Merck & Co
Average 90 stars, based on 1 article reviews
conformationally restricted sulfonamide 48 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
renin inhibitors containing conformationally restricted p1-p1′ dipeptide  (Mimetics)
90
Mimetics renin inhibitors containing conformationally restricted p1-p1′ dipeptide
New potential therapeutic targets for IBD with differentiated MoAs. The diversity of IBD pathological mechanisms represents an opportunity for novel treatment approaches. Examples of therapeutic candidates in preclinical development include LBPs, which restore eubiosis by decolonizing pathobionts and repopulating commensal microbiota. Supplementation of RvE1 and inhibition of PAI-1 induce enterocyte proliferation and mucosal healing. An inhibitor of MLCK prevents its trafficking to TJs, avoiding barrier junction damage. A neutralizing MAb against IgA-coated bacteria-derived toxins can also prevent barrier <t>damage.</t> <t>Inhibitors</t> of SPNS2 abrogate leukocyte trafficking to sites of inflammation. BRD4 and Fbxo3 antagonists inhibit proinflammatory mediators, and an inhibitor of GCPII may abrogate local neuroinflammatory signals. Opportunities for treatment of fibrotic complications include neutralizing anti-TL1A monoclonal antibodies and inhibitors of <t>ROCK.</t> Programmable biopolymers are in development to enable tissue reconstruction and healing of the fistula tract. Abbreviations: BRD4, bromodomain-containing protein 4; GCPII, glutamate carboxypeptidase II; IBD, inflammatory bowel diseases; IgA, immunoglobin A; LBP, live biotherapeutic product; MAb, monoclonal antibody; MLCK, myosin light chain kinase; MoA, mechanism of action; PAI-1, plasminogen activator inhibitor–1; ROCK, rho-associated coiled-coil-containing protein kinase; RvE1, resolvin E1; TJ, tight junction.
Renin Inhibitors Containing Conformationally Restricted P1 P1′ Dipeptide, supplied by Mimetics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/renin inhibitors containing conformationally restricted p1-p1′ dipeptide/product/Mimetics
Average 90 stars, based on 1 article reviews
renin inhibitors containing conformationally restricted p1-p1′ dipeptide - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


New potential therapeutic targets for IBD with differentiated MoAs. The diversity of IBD pathological mechanisms represents an opportunity for novel treatment approaches. Examples of therapeutic candidates in preclinical development include LBPs, which restore eubiosis by decolonizing pathobionts and repopulating commensal microbiota. Supplementation of RvE1 and inhibition of PAI-1 induce enterocyte proliferation and mucosal healing. An inhibitor of MLCK prevents its trafficking to TJs, avoiding barrier junction damage. A neutralizing MAb against IgA-coated bacteria-derived toxins can also prevent barrier damage. Inhibitors of SPNS2 abrogate leukocyte trafficking to sites of inflammation. BRD4 and Fbxo3 antagonists inhibit proinflammatory mediators, and an inhibitor of GCPII may abrogate local neuroinflammatory signals. Opportunities for treatment of fibrotic complications include neutralizing anti-TL1A monoclonal antibodies and inhibitors of ROCK. Programmable biopolymers are in development to enable tissue reconstruction and healing of the fistula tract. Abbreviations: BRD4, bromodomain-containing protein 4; GCPII, glutamate carboxypeptidase II; IBD, inflammatory bowel diseases; IgA, immunoglobin A; LBP, live biotherapeutic product; MAb, monoclonal antibody; MLCK, myosin light chain kinase; MoA, mechanism of action; PAI-1, plasminogen activator inhibitor–1; ROCK, rho-associated coiled-coil-containing protein kinase; RvE1, resolvin E1; TJ, tight junction.

Journal: Inflammatory Bowel Diseases

Article Title: Research-Based Product Innovation to Address Critical Unmet Needs of Patients with Inflammatory Bowel Diseases

doi: 10.1093/ibd/izab230

Figure Lengend Snippet: New potential therapeutic targets for IBD with differentiated MoAs. The diversity of IBD pathological mechanisms represents an opportunity for novel treatment approaches. Examples of therapeutic candidates in preclinical development include LBPs, which restore eubiosis by decolonizing pathobionts and repopulating commensal microbiota. Supplementation of RvE1 and inhibition of PAI-1 induce enterocyte proliferation and mucosal healing. An inhibitor of MLCK prevents its trafficking to TJs, avoiding barrier junction damage. A neutralizing MAb against IgA-coated bacteria-derived toxins can also prevent barrier damage. Inhibitors of SPNS2 abrogate leukocyte trafficking to sites of inflammation. BRD4 and Fbxo3 antagonists inhibit proinflammatory mediators, and an inhibitor of GCPII may abrogate local neuroinflammatory signals. Opportunities for treatment of fibrotic complications include neutralizing anti-TL1A monoclonal antibodies and inhibitors of ROCK. Programmable biopolymers are in development to enable tissue reconstruction and healing of the fistula tract. Abbreviations: BRD4, bromodomain-containing protein 4; GCPII, glutamate carboxypeptidase II; IBD, inflammatory bowel diseases; IgA, immunoglobin A; LBP, live biotherapeutic product; MAb, monoclonal antibody; MLCK, myosin light chain kinase; MoA, mechanism of action; PAI-1, plasminogen activator inhibitor–1; ROCK, rho-associated coiled-coil-containing protein kinase; RvE1, resolvin E1; TJ, tight junction.

Article Snippet: 212 Rho-associated coiled-coil-containing protein kinases (ROCKs) are a key mediator of these processes, but systemic inhibition of these kinases is toxic, leading several groups, including RedX Pharma, to develop and evaluate gut-restricted ROCK inhibitors for the prevention and treatment of strictures ( Fig. 4 ), with promising preclinical results reported.

Techniques: Inhibition, Derivative Assay